气溶向肺部输送聚电解质表面活性剂-抗菌纳米颗粒
Yadiel Varela Soler1, Amanda S Padilla-López2,3, Sughosha Rao2
1Department of Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ, 08854, USA.
Pharmaceutical research
|January 9, 2026
概括
聚电解质表面活性剂 (PS) 显示出在囊性纤维化症中雾化肺部药物输送的前景. 纳米粒子在雾化后保持了大小和活性,证明了小鼠的安全性和肺部保留.
科学领域:
- 纳米技术 纳米技术
- 药物通过肺部输送.
- 囊性纤维化研究研究
背景情况:
- 肺部感染,特别是Pseudomonas aeruginosa,在囊性纤维化患者中很普遍.
- 目前的 nebulized 抗生素治疗由于肺的物理化学环境而面临限制.
- 之前的研究已经确定了多电解质表面活性剂 (PS) 作为有效的阴离子抗微生物的体外输送系统.
研究的目的:
- 评估聚电解质表面活性剂 (PS) 在雾化肺部药物输送方面的潜力.
- 为了评估PS纳米粒子在雾化后的特性和有效性.
- 在体内确定PS纳米颗粒的安全性和生物分布.
主要方法:
- PS纳米颗粒的雾化,然后进行大小和抗菌活性评估.
- 在肺上皮细胞和红细胞的体外毒性测试.
- 在吸入后在小鼠体内生物分布和炎症标志物分析.
主要成果:
- 聚氨酸纳米颗粒表现出粘合性质,并在雾化后保持大小和活性.
- 没有观察到体外毒性; 增加了上皮细胞活力.
- 超过70%的吸入纳米颗粒在24小时后被保留在小鼠肺部,对其他器官的分布最小.
- 在肝脏和脏中观察到轻微可控的炎症反应 (增加IL-6和IL-18).
结论:
- 聚电解质表面活性剂 (PS) 代表了用于肺部药物输送的有前途的纳米技术.
- 评估的PS纳米粒子在雾化中安全有效.
- 这种方法有可能改善囊性纤维化肺部感染的治疗.
相关概念视频
01:23Inhaled Medications
728
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
728
01:05Breathing
64.1K
The process of breathing, inhaling and exhaling, involves the coordinated movement of the chest wall, the lungs, and the muscles that move them. Two muscle groups with important roles in breathing are the diaphragm, located directly below the lungs, and the intercostal muscles, which lie between the ribs. When the diaphragm contracts, it moves downward, increasing the volume of the thoracic cavity and creating more room for the lungs to expand. When the intercostal muscles contract, the ribs...
64.1K